

**Table S1. Primer sequences.**

<b>Target gene</b>	<b>Reverse (5'→3')</b>	<b>Forward (5'→3')</b>
GAPDH	TTTGAGGGTGCAGCGAACTT	ACAGCAACAGGGTGGTGGAC
Atf4	CCAAGGAGCCGATGAGATAGTT	GACAGGCGGCAACGATACT
Mt-nd2	GGCGCCAACAAAGACTGATG	TACCCGAAGTCACCCAAGGA
Mt-nd4	GTGTGGGAAGGTTGGAGGTT	GCCAACCTAGCACTACCACC
Mt-nd3	AGGGGGAGTAGTAAGGCGAT	GACCCAACAAGTTCTGCACG
Mt-co2	AAGTGCTGGGCAAAGAATGC	CTGATGACTGCCCAACTCCC
Ndufv3	GAGGGGAGCTTTTGGACAGTG	ATAAAAAGGCGGCAGGACCAA
Mt-nd1	GAATAGGGCGAATGGTCCTG	CGAGCTCCCTTCGACTTAAC
Edn1	GAAACTGTAGAAGCCGGACA	AGCAACAGCATCAAGACCTC
Socs3	TCTTCTGCTGGGCTAACTGG	AACGGTCACCTGGACTCCTAT
Lif	GTATGGCGCAGGTGGCATT	ATGAAGGTCTTGGCCACAGG

**Table S2. Quality of the RNA-sequence data of each sample. SLPQ1, treatment group after SLPQ1 interacted with RIN-14B cells; Control, control group.**

Sample	Raw reads (bp)	Clean reads (bp)	Q20 (%)	Q30 (%)
Control 1	67171142	66653124	98.18	94.43
Control 2	64547394	64091508	98.17	94.39
Control 3	72493818	71963872	98.14	94.33
SLPQ1	66118396	65629050	98.17	94.43
SLPQ2	69144106	68603916	98.08	94.19
SLPQ3	73645230	73126506	98.25	94.61